These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 7344226)
1. Influence of therapy on causes of death in polycythemia vera. Wasserman LR; Balcerzak SP; Berk PD; Berlin NI; Donovan PB; Dresch C; Ellis JT; Goldberg JD; Landaw SA; Laszlo J; McIntyre OR; Najean Y; Pisciotta AV; Silverstein MN; Tartaglia AP; Tatarsky I; Weinfeld A Trans Assoc Am Physicians; 1981; 94():30-8. PubMed ID: 7344226 [No Abstract] [Full Text] [Related]
2. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665 [TBL] [Abstract][Full Text] [Related]
3. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. Berk PD; Goldberg JD; Silverstein MN; Weinfeld A; Donovan PB; Ellis JT; Landaw SA; Laszlo J; Najean Y; Pisciotta AV; Wasserman LR N Engl J Med; 1981 Feb; 304(8):441-7. PubMed ID: 7005681 [TBL] [Abstract][Full Text] [Related]
4. [Clinical course and transformation of polycythemia vera and its relation to applied therapy]. Burger T; Schmelczer M; Molnár L; Pajor L; Koszorús S Orv Hetil; 1987 Dec; 128(52):2723-30. PubMed ID: 3431872 [No Abstract] [Full Text] [Related]
5. Laboratory investigations and prediction of thrombotic risk in polycythemia vera. Boneu B Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):183-5. PubMed ID: 8036139 [TBL] [Abstract][Full Text] [Related]
6. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. Marchioli R; Finazzi G; Landolfi R; Kutti J; Gisslinger H; Patrono C; Marilus R; Villegas A; Tognoni G; Barbui T J Clin Oncol; 2005 Apr; 23(10):2224-32. PubMed ID: 15710945 [TBL] [Abstract][Full Text] [Related]
7. [Efficacious treatment of a fatal blood disease: polycythemia vera]. Sánchez Fayos J; Román Barbero A; Nevado Reviriego I Sangre (Barc); 1997 Jun; 42(3):215-8. PubMed ID: 9381264 [No Abstract] [Full Text] [Related]
8. Hyperviscosity in polycythemia vera and other red cell abnormalities. Kwaan HC; Wang J Semin Thromb Hemost; 2003 Oct; 29(5):451-8. PubMed ID: 14631544 [TBL] [Abstract][Full Text] [Related]
13. Polycythemia vera: diagnosis, treatment, and relationship to leukemia. Walsh JR Geriatrics; 1978 May; 33(5):61-3, 66-9. PubMed ID: 640388 [No Abstract] [Full Text] [Related]
14. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Passamonti F; Malabarba L; Orlandi E; Baratè C; Canevari A; Brusamolino E; Bonfichi M; Arcaini L; Caberlon S; Pascutto C; Lazzarino M Haematologica; 2003 Jan; 88(1):13-8. PubMed ID: 12551821 [TBL] [Abstract][Full Text] [Related]
15. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Nand S; Stock W; Godwin J; Fisher SG Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610 [TBL] [Abstract][Full Text] [Related]
18. Common hematologic problems: diagnosis and treatment. Freedman ML Geriatrics; 1983 Apr; 38(4):119-23, 127-30, 134. PubMed ID: 6832586 [No Abstract] [Full Text] [Related]
19. Platelet production rate in polycythemia vera after myelosuppressive therapy. Kutti J Acta Med Scand; 1972 Sep; 192(3):161-4. PubMed ID: 5055260 [No Abstract] [Full Text] [Related]
20. Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia. Haq AU Am J Hematol; 1990 Oct; 35(2):110-3. PubMed ID: 2399902 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]